INS and type 2 diabetes mellitus: This trial was more rigorous with the fasting blood glucose target.[17] In addition, Novo Nordisk conducted ONWARDS1, 3, and 5 to evaluate the efficacy and safety of icodec in insulin-naive patients with T2D.[26] However, as the full data of these 3 trials have not been published, they were not included in our meta-analysis.